Sole bookrunner Stifel, co-manager Maxim Group will assist with sale
By Devika Patel
Knoxville, Tenn., Oct. 17 - Tekmira Pharmaceuticals Corp. said it priced a $30 million public sale of its common stock. The deal was announced Wednesday and has a $4.5 million greenshoe.
The company will sell 3.75 million common shares at $8.00 per share. The price per share is a 9.3% discount to the Oct. 16 closing share price of $8.82.
Stifel is the sole bookrunner.
Settlement is expected Oct. 22.
Proceeds will be used for working capital and general corporate purposes, including research and development programs.
The biopharmaceutical company is based in Vancouver, B.C.
| Issuer: | Tekmira Pharmaceuticals Corp.
|
| Issue: | Common stock
|
| Amount: | $30 million
|
| Greenshoe: | $4.5 million
|
| Shares: | 3.75 million
|
| Price: | $8.00
|
| Warrants: | No
|
| Bookrunner: | Stifel
|
| Co-manager: | Maxim Group LLC
|
| Announcement date: | Oct. 16
|
| Pricing date: | Oct. 17
|
| Settlement date: | Oct. 22
|
| Stock symbol: | Nasdaq: TKMR
|
| Stock price: | $8.82 at close Oct. 16
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
